The Ultimate Finasteride Guide for 2026: Everything in One Place

Mechanism, results timeline, side effects data, pricing, topical vs oral, dutasteride comparison, GLP-1 hair loss, and treatment decision tree — backed by clinical evidence throughout.

How Finasteride Works

Finasteride is a competitive, specific inhibitor of Type II and Type III 5-alpha reductase isoenzymes. It blocks the conversion of testosterone to dihydrotestosterone (DHT) — the hormone that drives follicle miniaturization in androgenetic alopecia.

At 1mg daily, finasteride reduces serum DHT by approximately 65–70% and scalp DHT by approximately 64%. It forms a stable complex with the enzyme that has a turnover half-life of roughly 30 days — which is why missing a single dose doesn't matter much.

Testosterone rises slightly (10–20%) when DHT production is blocked, but this increase stays within the normal physiologic range. Finasteride has minimal activity against Type I 5-alpha reductase (the IC50 is 100-fold lower for Type II than Type I), which is why it can't achieve more than approximately 70% DHT reduction — and why dutasteride, which inhibits all three isoenzymes, can go further.

Full article: How Finasteride Works — The Complete Science

Results Timeline

Weeks 1–2: DHT begins dropping. No visible changes.

Weeks 2–8: Possible temporary shedding ("dread shed") as resting follicles are pushed into a new growth cycle. This is typically a positive indicator.

Months 3–6: Hair loss slows. Early stabilization visible for most men.

Months 6–12: Visible improvement for most responders — thicker hair, better coverage, increased density.

Year 1–5: Merck trials: 48% improvement at 12 months climbing to 66% at 48 months.

Year 5–10: Japanese 10-year study: improvement continued from year 5 through year 10 (p<0.001). 99.1% showed improvement or prevention of progression.

Full article: Finasteride Results Month by Month

Side Effects: The Actual Data

Side effects decreased over time — dropping to ≤0.3% by year 5. The 10-year study: 6.8% adverse reactions, all mild, zero serious events. The nocebo effect is a significant confounding factor — the Mondaini study showed 43.6% side effect reporting when men were informed vs 15.3% uninformed.

Full article: Side Effects by the Numbers · PFS Evidence Review · The Nocebo Effect

Cost in 2026

Full article: Finasteride Cost Guide 2026

Topical vs Oral Finasteride

The Piraccini Phase III trial (458 men): topical 0.25% increased hair count comparably to oral, with plasma finasteride levels over 100-fold lower. Serum DHT reduction: 34.5% (topical) vs 55.6% (oral). The 2026 Gupta pharmacovigilance study found significantly fewer adverse event reports for topical vs oral across all categories.

Trade-off: lower systemic exposure (potentially fewer side effects) but less DHT suppression (potentially less effective for aggressive AGA). Happy Head offers custom compounded topical formulations.

Full article: Topical vs Oral Finasteride

Dutasteride Comparison

Dutasteride inhibits all 3 isoenzymes of 5-alpha reductase and reduces DHT by 92–98% vs finasteride's ~70%. Meta-analysis (Zhou 2019): +28.57 hairs over finasteride. But dutasteride's half-life is 4–5 weeks vs finasteride's 6–8 hours — meaning side effects persist much longer after discontinuation. Approved for AGA only in Japan, South Korea, and Taiwan.

Recommendation: try finasteride first. Switch to dutasteride if inadequate response after 12+ months.

Full article: Finasteride vs Dutasteride · Switching Guide

Combination Therapy

The 2025 Xia meta-analysis (18 RCTs) ranked finasteride + minoxidil as the #1 combination. Finasteride blocks the cause (DHT), minoxidil stimulates growth — different mechanisms, synergistic results. Adding microneedling (Chang 2025) achieved the highest self-assessment scores at 80% ≥3.

Full article: Finasteride + Minoxidil — Why Use Both

GLP-1 Weight Loss and Hair Loss

GLP-1 medications can cause both telogen effluvium (temporary, diffuse) and unmask androgenetic alopecia (progressive, patterned). The 2026 GWU study (~550,000 patients) confirmed elevated risk of both. Minoxidil alone is insufficient for the AGA component — finasteride is needed to block the DHT surge from hormonal shifts during rapid weight loss.

No drug interactions exist between finasteride and GLP-1 medications.

Full article: GLP-1 and Hair Loss · Treatment Ladder · Drug Interactions

Treatment Decision Tree

Noticing hair loss → Get diagnosed (TE or AGA?)

If TE: Nutritional optimization + minoxidil + time. Usually resolves in 6–12 months.

If AGA (early, Norwood I–III): Finasteride 1mg + minoxidil 5%. Consider topical finasteride if concerned about systemic side effects.

If AGA (moderate, Norwood III–IV): Same protocol + microneedling. Consider dutasteride if finasteride response plateaus after 12 months.

If AGA (advanced, Norwood V+): Treatment can slow further loss but significant regrowth is less likely. Hair transplant consultation may be appropriate. Finasteride still recommended to protect remaining hair and transplanted follicles.

How to Get Started